JP5893640B2 - Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用 - Google Patents

Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用 Download PDF

Info

Publication number
JP5893640B2
JP5893640B2 JP2013545118A JP2013545118A JP5893640B2 JP 5893640 B2 JP5893640 B2 JP 5893640B2 JP 2013545118 A JP2013545118 A JP 2013545118A JP 2013545118 A JP2013545118 A JP 2013545118A JP 5893640 B2 JP5893640 B2 JP 5893640B2
Authority
JP
Japan
Prior art keywords
oprf
seq
fusion protein
protein
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013545118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014504297A5 (enExample
JP2014504297A (ja
Inventor
クレイド、クリストフ
シュレーゲル、ロベール
ヴェシュトリトシュニク、ケルスティン
Original Assignee
ファルネファ オーストリア ゲーエムベーハー
ファルネファ オーストリア ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファルネファ オーストリア ゲーエムベーハー, ファルネファ オーストリア ゲーエムベーハー filed Critical ファルネファ オーストリア ゲーエムベーハー
Publication of JP2014504297A publication Critical patent/JP2014504297A/ja
Publication of JP2014504297A5 publication Critical patent/JP2014504297A5/ja
Application granted granted Critical
Publication of JP5893640B2 publication Critical patent/JP5893640B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013545118A 2010-12-23 2011-03-18 Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用 Expired - Fee Related JP5893640B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426760P 2010-12-23 2010-12-23
US61/426,760 2010-12-23
PCT/EP2011/054127 WO2012084272A1 (en) 2010-12-23 2011-03-18 Oprf/i agents and their use in hospitalized and other patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016032315A Division JP2016147867A (ja) 2010-12-23 2016-02-23 Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用

Publications (3)

Publication Number Publication Date
JP2014504297A JP2014504297A (ja) 2014-02-20
JP2014504297A5 JP2014504297A5 (enExample) 2014-04-17
JP5893640B2 true JP5893640B2 (ja) 2016-03-23

Family

ID=44210049

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013545118A Expired - Fee Related JP5893640B2 (ja) 2010-12-23 2011-03-18 Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用
JP2016032315A Pending JP2016147867A (ja) 2010-12-23 2016-02-23 Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016032315A Pending JP2016147867A (ja) 2010-12-23 2016-02-23 Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用

Country Status (11)

Country Link
US (1) US20130266575A1 (enExample)
EP (1) EP2655402A1 (enExample)
JP (2) JP5893640B2 (enExample)
KR (1) KR20130133212A (enExample)
CN (1) CN103270047A (enExample)
AU (1) AU2011348396A1 (enExample)
BR (1) BR112013016254A2 (enExample)
CA (1) CA2822684A1 (enExample)
MX (1) MX2013007146A (enExample)
WO (1) WO2012084272A1 (enExample)
ZA (1) ZA201304235B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987344B2 (en) 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CN103983793A (zh) * 2014-05-29 2014-08-13 上海理工大学 一种含丽春红的蛋白质芯片点样缓冲液及其制备方法
EP3185897A4 (en) * 2014-08-29 2018-05-02 Sorrento Therapeutics, Inc. Antibody therapeutics that bind oprf and opri
CN107922482A (zh) 2015-05-01 2018-04-17 英伊布里克斯有限合伙公司 Iii型分泌系统靶向分子
WO2016193402A1 (en) 2015-06-03 2016-12-08 Valneva Austria Gmbh Pseudomonas vaccine
CN114106178A (zh) 2015-07-16 2022-03-01 印希比股份有限公司 多价和多特异性结合dr5的融合蛋白
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
CN117222740A (zh) * 2022-06-07 2023-12-12 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
CN116251178A (zh) * 2023-03-28 2023-06-13 吉林农业大学 一种铜绿假单胞菌疫苗及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494672A (en) * 1989-04-28 1996-02-27 S.P.I. Synthetic Peptides Incorporated Pseudomonas peptide composition and method
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
EP0717106B1 (en) * 1994-12-16 2000-03-15 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US20040197341A1 (en) * 2001-09-03 2004-10-07 Jean-Claude Pechere Therapeutic process for p. aeruginosa infections using macrolide antibiotics
AU2002340683C1 (en) * 2001-11-13 2009-11-12 Id Biomedical Corporation Of Quebec Polypeptides of pseudomonas aeruginosa
KR101399678B1 (ko) * 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
EP1623229A2 (en) 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
CN101076342A (zh) * 2004-12-17 2007-11-21 维纳斯药业有限公司 用于对治疗感染提供总解决方案的抗生素组合
EP1921142A1 (en) 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
US9987344B2 (en) * 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations

Also Published As

Publication number Publication date
ZA201304235B (en) 2014-09-25
AU2011348396A1 (en) 2013-07-04
EP2655402A1 (en) 2013-10-30
CA2822684A1 (en) 2012-06-28
CN103270047A (zh) 2013-08-28
US20130266575A1 (en) 2013-10-10
JP2016147867A (ja) 2016-08-18
BR112013016254A2 (pt) 2017-07-11
KR20130133212A (ko) 2013-12-06
WO2012084272A1 (en) 2012-06-28
MX2013007146A (es) 2013-11-01
AU2011348396A2 (en) 2013-07-11
JP2014504297A (ja) 2014-02-20

Similar Documents

Publication Publication Date Title
US20130266575A1 (en) OprF/I AGENTS AND USE THEREOF IN HOSPITALIZED AND OTHER PATIENTS
CN111690059B (zh) 一种抗SARS-CoV-2的单克隆抗体1D7
CN111718411B (zh) 一种抗SARS-CoV-2的单克隆抗体1F2
JP6048845B2 (ja) ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質
CN112521494B (zh) 一种抗SARS-CoV-2的单克隆抗体2B11
EP3805255A1 (en) Acinetobacter baumannii immunogenic protein and composition and application thereof
AU2014314222B2 (en) Stable polypeptides binding to human complement C5
Hu et al. Preformulation characterization and stability assessments of secretory IgA monoclonal antibodies as potential candidates for passive immunization by oral administration
WO2007138328A2 (en) Novel applications for staphylococcus aureus sbi protein
WO2025241209A1 (zh) Rsv融合前f蛋白的突变体及其制备和应用
TW202102204A (zh) 包含抗ｉｌ－５抗體的醫藥組成物及其用途
Burkhardt et al. Assessment of the impact of manufacturing changes on the physicochemical properties of the recombinant vaccine carrier ExoProtein A
WO2016073860A1 (en) Binding molecules specific for staphylococcus protein a and uses thereof
CN114163504A (zh) SARS-CoV-2 S蛋白RBD区中和表位肽及其应用
US20160362480A1 (en) Novel oprf/i fusion proteins, their preparation and use
CN105980562B (zh) 源于细菌表面受体蛋白的免疫原性组合物和疫苗
HK1188799A (en) Oprf/i agents and their use in hospitalized and other patients
CN113817051B (zh) 一种抗SARS-CoV-2的单克隆抗体1B6
US10774135B2 (en) Variant antibodies that bind AIP2
CN105542003A (zh) 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
JP2022538438A (ja) 百日咳毒素結合タンパク質
KR20250095812A (ko) 항-sfts 바이러스 항체 및 이의 용도
TW202100540A (zh) 一種以重組毒素製作抗蛇毒血清方法
HK40112146B (zh) Rsv融合前f蛋白的突变体及其制备和应用
CN113817050A (zh) 一种抗SARS-CoV-2的单克隆抗体1H8

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150824

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160224

R150 Certificate of patent or registration of utility model

Ref document number: 5893640

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees